Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial

Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria LMC Diabetes and Endocrinology, Brampton, Ontario, Canada Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, UK Novo Nordisk A/S, Søborg, Denmark Diabetes Research Centre, University of Leicester, Leicester, UK Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, California, USA Li Ka Shing Knowledge Institute, Division of Endocrinology & Metabolism, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada Scripps Whittier Diabetes Institute, La Jolla, California, USA

[1]  Y. Saisho.  Review for "Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial" , 2021 .

[2]  S. Heller,et al.  Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE , 2020, Diabetes, obesity & metabolism.

[3]  Lawrence A Leiter,et al.  Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial , 2020, Diabetologia.

[4]  T. Pieber,et al.  Commentary to “Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec” by Kawaguchi et al. Diabetes Therapy 2019 , 2020, Diabetes Therapy.

[5]  J. Rosenstock,et al.  Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial , 2020, Diabetes, obesity & metabolism.

[6]  W. Aronow,et al.  Severe Hypoglycemia and Risk of Subsequent Cardiovascular Events: Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2019, Cardiology in review.

[7]  B. Zinman,et al.  Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11) , 2019, Diabetes Therapy.

[8]  Y. Kumeda,et al.  Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec , 2019, Diabetes Therapy.

[9]  Lawrence A Leiter,et al.  Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478) , 2019, Journal of diabetes science and technology.

[10]  M. Shlipak,et al.  Serum albumin concentration and risk of end-stage renal disease: the REGARDS study , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  J. Rosenstock,et al.  More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial , 2018, Diabetes Care.

[12]  V. Fonseca,et al.  Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients. , 2017, Endocrinology and metabolism clinics of North America.

[13]  S. Bajaj,et al.  Consensus statement on insulin therapy in chronic kidney disease. , 2017, Diabetes research and clinical practice.

[14]  R. Bergenstal,et al.  Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes , 2016, Diabetes technology & therapeutics.

[15]  J. Gerich,et al.  Hypoglycemia, chronic kidney disease, and diabetes mellitus. , 2014, Mayo Clinic proceedings.

[16]  R. Becker,et al.  Low within- and between-day variability in exposure to new insulin glargine 300 U/ml , 2015, Diabetes, obesity & metabolism.

[17]  T. Heise,et al.  A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance , 2014, Clinical Pharmacokinetics.

[18]  Simon R. Heller,et al.  Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. , 2013, The Journal of clinical endocrinology and metabolism.

[19]  L Nosek,et al.  Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes , 2012, Diabetes, obesity & metabolism.

[20]  U. Ribel,et al.  Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin , 2012, Pharmaceutical Research.